

Daniel Wolff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/964360/publications.pdf>

Version: 2024-02-01

90
papers

6,594
citations

147726

31
h-index

66879

78
g-index

92
all docs

92
docs citations

92
times ranked

6559
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
2	Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 640-645.	2.0	444
3	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1-17.	2.0	311
4	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
5	EBMT~NIH~CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	1.3	243
6	Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1611-1628.	2.0	226
7	Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. <i>Brain</i> , 2010, 133, 2852-2865.	3.7	189
8	Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 1283-1295.	1.3	154
9	Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the German~Austrian~Swiss Consensus Conference on Clinical Practice in Chronic GVHD. <i>Cornea</i> , 2012, 31, 299-310.	0.9	128
10	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
11	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haematopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e28-e39.	2.2	94
12	Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. <i>Vaccine</i> , 2011, 29, 2825-2833.	1.7	93
13	Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning. <i>Journal of Clinical Oncology</i> , 2010, 28, 3344-3351.	0.8	83
14	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.	0.6	83
15	Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation~Results from a Single-Center Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1781-1791.	2.0	78
16	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
17	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
18	Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1707-1717.	2.0	57

#	ARTICLE	IF	CITATIONS
19	Biomarkers in chronic graft-versus-host disease: quo vadis?. Bone Marrow Transplantation, 2018, 53, 832-837.	1.3	55
20	Recipient NOD2/CARD15 Variants: A Novel Independent Risk Factor for the Development of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 67-74.	2.0	54
21	Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical Practice. Biology of Blood and Marrow Transplantation, 2011, 17, 167-175.	2.0	54
22	Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. Bone Marrow Transplantation, 2015, 50, 3-9.	1.3	51
23	Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers. Biology of Blood and Marrow Transplantation, 2013, 19, 767-776.	2.0	49
24	German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. British Journal of Dermatology, 2011, 165, 18-29.	1.4	48
25	Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia, 2014, 28, 842-852.	3.3	47
26	CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 250-258.	2.0	47
27	Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transplantation, 2014, 49, 49-54.	1.3	42
28	Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transplantation, 2021, 56, 2079-2087.	1.3	37
29	Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 595.	2.2	36
30	Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: Report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transplant International, 2011, 24, 867-879.	0.8	35
31	Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 948-954.	1.3	34
32	Pharmaceutical and Cellular Strategies in Prophylaxis and Treatment of Graft-Versus-Host Disease. Current Pharmaceutical Design, 2009, 15, 1974-1997.	0.9	33
33	Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease. Bone Marrow Transplantation, 2002, 29, 357-360.	1.3	31
34	Muscle Cramps and Neuropathies in Patients with Allogeneic Hematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. PLoS ONE, 2012, 7, e44922.	1.1	28
35	Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica, 2021, 106, 363-374.	1.7	26
36	Validation of the grip test and human activity profile for evaluation of physical performance during the intermediate phase after allogeneic hematopoietic stem cell transplantation. Supportive Care in Cancer, 2013, 21, 1121-1129.	1.0	24

#	ARTICLE	IF	CITATIONS
37	The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. <i>Haematologica</i> , 2018, 103, 1698-1707.	1.7	24
38	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
39	Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 175-190.	1.4	23
40	Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. <i>Infection</i> , 2012, 40, 153-161.	2.3	22
41	The lack of memory B cells including T cell independent IgM+ α fIgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. <i>Transplant International</i> , 2012, 25, 87-96.	0.8	22
42	Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center. <i>Bone Marrow Transplantation</i> , 2013, 48, 129-134.	1.3	22
43	Comorbidity burden in patients with chronic GVHD. <i>Bone Marrow Transplantation</i> , 2013, 48, 1429-1436.	1.3	21
44	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. <i>Bone Marrow Transplantation</i> , 2014, 49, 1412-1418.	1.3	21
45	IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 847-853.	0.8	21
46	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
47	Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1613-1619.	1.2	20
48	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <i>Bone Marrow Transplantation</i> , 2018, 53, 490-494.	1.3	19
49	Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset. <i>Annals of Hematology</i> , 2017, 96, 299-310.	0.8	17
50	Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 602547.	2.2	17
51	Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD. <i>Annals of Hematology</i> , 2016, 95, 493-499.	0.8	16
52	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	0.6	16
53	Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 676756.	2.2	15
54	Predicting survival using clinical risk scores and non-HLA immunogenetics. <i>Bone Marrow Transplantation</i> , 2015, 50, 1445-1452.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Successful treatment of a refractory skin ulcer in chronic cutaneous GvHD after allogeneic HSCT with split-thickness skin allografting from the stem cell donor. <i>Bone Marrow Transplantation</i> , 2012, 47, 1368-1369.	1.3	13
56	High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 337.e1-337.e10.	0.6	13
57	Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1450-1455.	2.0	12
58	Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease—results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. <i>Bone Marrow Transplantation</i> , 2021, 56, 243-256.	1.3	11
59	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2021, 137, 2403-2416.	0.6	11
60	Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis. <i>Annals of Hematology</i> , 2021, 100, 779-787.	0.8	10
61	1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 419-433.	1.3	8
62	Methotrexate-Albumin and Aminopterin-Albumin Effectively Prevent Experimental Acute Graft-versus-Host Disease. <i>Transplantation</i> , 2006, 82, 527-533.	0.5	7
63	Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. <i>Immunopharmacology and Immunotoxicology</i> , 2009, 31, 595-600.	1.1	7
64	Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 2181-2190.	0.8	7
65	Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation — A single center retrospective efficacy analysis. <i>Vaccine</i> , 2021, 39, 4742-4750.	1.7	7
66	Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution. <i>Immunopharmacology and Immunotoxicology</i> , 2014, 36, 158-164.	1.1	6
67	Retinal Involvement in a Patient with Cerebral Manifestation of Chronic Graft-Versus-Host-Disease. <i>Oncology Research and Treatment</i> , 2015, 38, 532-534.	0.8	6
68	Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. <i>Radiotherapy and Oncology</i> , 2015, 116, 287-293.	0.3	6
69	Prospective Evaluation of the NIH Staging Criteria in Chronic GVHD and Correlation to Quality of Life - Results of a German Multicenter Validation Trial.. <i>Blood</i> , 2007, 110, 42-42.	0.6	5
70	Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia. <i>International Journal of Immunogenetics</i> , 2016, 43, 404-412.	0.8	4
71	NOD2/CARD15 Variants of Donor and Recipient as Critical Risk Factors for the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 144-144.	0.6	4
72	Bronchiolitis Obliterans: Pleading for a Pragmatic Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 591-593.	2.0	3

#	ARTICLE	IF	CITATIONS
73	Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation—a retrospective analysis on seven patients. <i>Annals of Hematology</i> , 2019, 98, 1867-1875.	0.8	3
74	Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis. <i>Blood</i> , 2011, 118, 1019-1019.	0.6	3
75	A few steps on the long road toward biomarkers in GVHD. <i>Blood</i> , 2020, 135, 1196-1197.	0.6	2
76	Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN- γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. <i>Diagnostics</i> , 2021, 11, 312.	1.3	2
77	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> . 2022, 57, 1150-1163.	1.3	2
78	Treatment options for graft-versus-host disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 731-743.	0.5	1
79	Human bocavirus 1 respiratory tract reactivations or reinfections in two adults, contributing to neurological deficits and death. <i>Access Microbiology</i> , 2021, 3, 000237.	0.2	1
80	Comorbidity Significantly Impairs Quality Of Life In Patients After Allogeneic Hematopoietic Stem Cell Transplantation — Results From The Prospective German Multicenter Validation Trial. <i>Blood</i> , 2013, 122, 2073-2073.	0.6	1
81	Development and Preliminary Testing Of The Post-Transplant Multimorbidity Index (PTMI). <i>Blood</i> , 2013, 122, 2076-2076.	0.6	1
82	Allogeneic Blood Stem Cell Transplantation in Patients with Hematologic Diseases after Conditioning with Treosulfan and Fludarabine.. <i>Blood</i> , 2005, 106, 2744-2744.	0.6	1
83	Joint effort to target the orphan of the orphan. <i>Blood</i> , 2019, 134, 224-225.	0.6	0
84	Influence of Hematopoietic Cell Lysate Vaccinations and Dendritic Cell Enriched Marrow Grafts on Engraftment after Nonmyeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5231-5231.	0.6	0
85	Incidence and Outcome of Non-CMV Viral Infections in 202 Consecutive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients.. <i>Blood</i> , 2007, 110, 1965-1965.	0.6	0
86	Severity of Chronic Gvhd and Personality Determines Quality of Life and the Activity Profile: Results of a Prospective German Multicenter Validation Trial. <i>Blood</i> , 2008, 112, 742-742.	0.6	0
87	ATG16 L1 a Additional Risk Factor for TRM After allogeneic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 1155-1155.	0.6	0
88	Prospective Validation of a Chronic GvHD-Specific Proteome Pattern (cGvHD-MS14) Post Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1970-1970.	0.6	0
89	Heparanase wildtype is associated with a reduced incidence of transplant-associated systemic vasculopathies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	0
90	Age Alone Does Not Matter?!. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 3-4.	0.6	0